Company: SCLXW
Filing Date: 2025-11-14
Form Type: 424B3
Source: 0001193125-25-283322
Chunk: 115

Company: Scilex Holding Co
Filing Date: 2025-11-14
Form: 424B3
Chunk 115
---
 foreseeable future as we support our clinical development to expand approved indications, continue our development of, and seek regulatory approvals for, our product candidates, and expand our corporate infrastructure. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. See Note 2 titled “ Liquidity and Going Concern ” to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information. Our existing cash and cash equivalents may be insufficient to enable us to fund our operating expenses, capital expenditure requirements, the repurchase of the Penny Warrants held by Oramed and to service our debt obligations (whether under the Oramed Note, the Tranche B Notes or otherwise) for at least the next 12 months. If these sources are insufficient to satisfy our liquidity requirements, we may seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions. Cash Flows The following table summarizes our cash flows for each of the periods presented (in thousands):

| Cash Flow Data:                                          |     | Nine Months Ended September 30, 
 2025                            |         |   |     | 2024 |         |   |
|:---------------------------------------------------------|:----|:--------------------------------|--------:|:--|:----|:-----|--------:|:--|
| Net cash proceeds from operating activities              |     | $                               |  21,287 |   |     | $    |  16,815 |   |
| Net cash used for investing activities                   |     |                                 |    (700 | ) |     |      |  (2,480 | ) |
| Net cash used for financing activities                   |     |                                 | (22,981 | ) |     |      | (10,948 | ) |
| Net change in cash, cash equivalents and restricted cash |     | $                               |  (2,394 | ) |     | $    |   3,387 |   |

Cash Flows from Operating Activities For the nine months ended September 30, 2025, net cash proceeds from operating activities were approximately $21.3 million, attributable to the changes in operating assets and liabilities that provided $98.3 million of cash and other non-cash reconciling items of $250.9 million related to transaction costs expensed related to Semnur Bussiness Combination,